UK Approves ALK’s First Needle-Free Adrenaline Spray for Children

Key Facts

In a move that highlights the shift toward patient-friendly pediatric care, the UK has granted marketing authorization for EURneffy 1 mg as the first needle-free adrenaline treatment for children. According to reports, the nasal spray is approved for children aged 4 and older weighing between 15–30 kg who are at risk of anaphylaxis. Developed by ALK, this treatment provides a non-invasive alternative to traditional adrenaline injections, aiming to simplify emergency response for severe allergic reactions.

This approval comes as the allergy treatment market evolves, with pharmaceutical firms increasingly seeking alternatives to traditional auto-injectors like the EpiPen. Compared to its peers, EURneffy represents a strategic milestone for Denmark-based ALK as it expands its footprint in major European markets. Per market data, needle-free options are expected to improve treatment compliance rates in schools and households, addressing a critical gap in the pediatric healthcare sector.